Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 384
Filter
1.
J Cutan Med Surg ; 28(3): 264-268, 2024.
Article in English | MEDLINE | ID: mdl-38481106

ABSTRACT

BACKGROUND: Suction blister epidermal grafting (SBEG) is currently one of the most prevalent surgical methods for stable vitiligo. OBJECTIVE: To investigate the long-term outcomes of vitiligo patients who underwent SBEG and to explore risk factors associated with postoperative relapse. METHODS: A retrospective cohort study was conducted in patients who underwent SBEG in our department between January 2016 and December 2022. Treatment outcomes, including repigmentation rate, adverse events, and postoperative relapse, were surveyed via telephone interview or out-=patient visit. Multivariate logistic regression models were used to assess the potential risk factors for postoperative relapse. Statistical significance was assumed at P < .05. RESULTS: A total of 253 patients were included with a repigmentation rate of 96% (243/253) after grafting. Common adverse events included cobblestone-like appearance (73.1%, 185/253) in the donor site, perigraft halo (46.2%, 117/253), and cobblestone-like appearance (26.1%, 66/253) in the recipient site. Postoperative relapse occurred in 20.1% of patients over a mean time of 29.7 months after grafting. Nonsegmental type of vitiligo and coexistence of autoimmune diseases were risk factors for postoperative relapse. CONCLUSION: SBEG is an effective surgical treatment for vitiligo with high repigmentation rate and good safety profile. Nonsegmental vitiligo and comorbid autoimmune diseases may increase the risk of postoperative relapse.


Subject(s)
Recurrence , Skin Transplantation , Vitiligo , Humans , Vitiligo/surgery , Male , Retrospective Studies , Female , Adult , Skin Transplantation/methods , Adolescent , Middle Aged , Young Adult , Risk Factors , Suction/methods , Epidermis/transplantation , Prognosis , Blister/surgery , Child , Treatment Outcome
5.
Sci Rep ; 12(1): 3184, 2022 02 24.
Article in English | MEDLINE | ID: mdl-35210511

ABSTRACT

Cryopreserved allogeneic cultured epidermis (CE) is used for treating second-degree burn wounds and diabetic foot ulcers; however, the need for cryopreservation limits its use. We have previously reported that CE accelerates wound healing irrespective of its viability and hypothesized that dehydrated CEs lacking living cells may act as an effective wound dressing. We prepared dried CE and investigated its morphological and physical properties and wound-healing effects and compared them with those of cryopreserved CE. Hematoxylin-eosin staining, immunostaining for basement membrane, and electron microscopy revealed that the morphologies of dried CE and cryopreserved CE were comparable and that the membrane structure was not damaged. The breaking strength, modulus of elasticity, and water permeability of dried CE were comparable with those of the cryopreserved CE. Furthermore, the levels of various active cytokines and chemokines in dried CE were comparable with those in cryopreserved CE. Dried CE applied to skin defect in diabetic mice significantly reduced the wound area and increased the new epithelium length 4 and 7 days after implantation, similar to that observed for cryopreserved CE. Consequently, dried CE had similar morphological and physical properties and wound-healing effects compared with those of cryopreserved CE and can be a physiological and versatile wound-dressing.


Subject(s)
Epidermal Cells/transplantation , Epidermis/transplantation , Keratinocytes/transplantation , Skin/pathology , Wound Healing , Animals , Cell Proliferation , Cell- and Tissue-Based Therapy , Cryopreservation , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/pathology , Disease Models, Animal , Epidermal Cells/cytology , Freeze Drying , Humans , Keratinocytes/cytology , Keratinocytes/metabolism , Mice , Mice, Inbred C57BL , Skin/metabolism
6.
Sci Rep ; 12(1): 393, 2022 01 10.
Article in English | MEDLINE | ID: mdl-35013472

ABSTRACT

The automated blister epidermal micrograft (ABEM) is a newly introduced surgical transplantation for refractory vitiligo. Comparative analysis of other surgical methods is lacking. We conducted a retrospective study to compare the efficacy, safety, and experience of ABEM with conventional suction blister epidermal graft (SBEG). A total of 118 anatomically based vitiligo lesions from 75 patients were included. The primary outcome was the degree of repigmentation; the patient and operator experience were evaluated. SBEG had a significantly greater incidence of repigmentation (p < 0.001), as measured by the Physician Global Assessment, as well as improvements in the Vitiligo Area Scoring Index, particularly on the face/neck area (p < 0.001). ABEM, on the contrary, had reduced donor harvest time, a better patient operative experience, and more significant Dermatology Life Quality Index improvements. In a subgroup of 38 lesions from ten patients who received both SBEG and ABEM concomitantly, there was no difference in the degree of repigmentation in the same recipient area. Overall, the degree of repigmentation for SBEG is higher than ABEM, especially in the mobilized region, and the cost is less expensive. On the contrary, ABEM requires less procedure learning curve and can supply a greater transplanting zone with shorter donor site recovery. Understanding the benefits and drawbacks of two blister grafting procedures is essential for optimal surgical outcomes for vitiligo grafting.


Subject(s)
Blister , Epidermis/transplantation , Skin Pigmentation , Skin Transplantation/methods , Vitiligo/surgery , Adult , Female , Graft Survival , Humans , Male , Middle Aged , Retrospective Studies , Skin Transplantation/adverse effects , Time Factors , Transplantation, Autologous , Treatment Outcome , Vitiligo/diagnosis , Vitiligo/physiopathology , Young Adult
7.
Dermatology ; 238(1): 167-169, 2022.
Article in English | MEDLINE | ID: mdl-33895742

ABSTRACT

Autologous non-cultured epidermal cellular grafting is the treatment of choice for patients with stable refractory vitiligo. Recently, studies have shown cost-effective alternatives for this procedure, superseding previous techniques that required large research facilities or expensive pre-packaged kits. We provide modifications to current techniques, including the use of individual Petri dishes to allow for processing larger skin grafts, hyfrecation instead of conventional manual dermabrasion of the recipient site to reduce scar formation as well as better margin delineation, and an intravenous giving set with a filter for improved filtration of the mixed cell population. These modifications facilitated sufficient skin repigmentation in a cost-effective outpatient setting.


Subject(s)
Epidermis/transplantation , Skin Transplantation/methods , Vitiligo/surgery , Adult , Humans , Male , Transplantation, Autologous , Treatment Outcome
11.
Eur J Dermatol ; 31(6): 759-770, 2021 Dec 01.
Article in French | MEDLINE | ID: mdl-34911675

ABSTRACT

The advent of tissue engineering and the clinical applications with cultured epidermal autograft (CEA) have improved the prognosis of severely burned patients. Marjolin ulcers (MUs) are a well-known complication of burns. These malignant neoplasm transformations of burn scars are usually squamous cell carcinomas with a higher incidence of regional metastases. Radical surgery remains the treatment of choice. To identify cases of malignant transformation occurring at sites of CEA in a cohort of 68 massively burned patients. A retrospective single-centre study was performed from April 2017 to June 2019 at the Military Hospital of Clamart (France). A total of 34 patients treated between 1991 and 2013 (including one post-mortem) were included. Four cases of squamous cell carcinoma occurred in areas previously covered by CEA. The data from clinical and histopathological examination as well as treatment modalities are presented. One patient died as a result of the evolution of his squamous cell carcinoma, and two others required salvage amputation due to locoregional recurrence. The prevalence of these CEA-MUs is estimated at between 5.9% and 11.7% and the person-time incidence rate of CEA-related MUs is about 5.9 per 1,000 persons-years. In our study, the average time to malignant transformation seems considerably shortened (32-35 years for "classic burn MU" versus 15.7 years for CEA-MU). This first documented case series of CEA-MUs demonstrates the need to inform caregivers and educate patients. Further studies are needed to specify the true incidence of CEA-graft site malignancy.


Subject(s)
Burns/pathology , Burns/surgery , Carcinoma, Squamous Cell/pathology , Cell Transformation, Neoplastic , Epidermis/transplantation , Skin Neoplasms/pathology , Skin Ulcer/pathology , Adult , Burns/complications , Cells, Cultured , Child , Female , Humans , Male , Middle Aged , Retrospective Studies , Skin Ulcer/etiology , Transplantation, Autologous
12.
N Engl J Med ; 385(24): 2264-2270, 2021 12 09.
Article in English | MEDLINE | ID: mdl-34881838

ABSTRACT

Inherited junctional epidermolysis bullosa is a severe genetic skin disease that leads to epidermal loss caused by structural and mechanical fragility of the integuments. There is no established cure for junctional epidermolysis bullosa. We previously reported that genetically corrected autologous epidermal cultures regenerated almost an entire, fully functional epidermis on a child who had a devastating form of junctional epidermolysis bullosa. We now report long-term clinical outcomes in this patient. (Funded by POR FESR 2014-2020 - Regione Emilia-Romagna and others.).


Subject(s)
Epidermis/transplantation , Epidermolysis Bullosa, Junctional/therapy , Keratinocytes/transplantation , Transduction, Genetic , Transgenes , Cell Self Renewal , Cells, Cultured/transplantation , Child , Clone Cells , Epidermis/pathology , Epidermolysis Bullosa, Junctional/genetics , Epidermolysis Bullosa, Junctional/pathology , Follow-Up Studies , Genetic Diseases, Inborn/pathology , Genetic Diseases, Inborn/therapy , Genetic Therapy , Genetic Vectors , Humans , Keratinocytes/cytology , Keratinocytes/physiology , Male , Regeneration , Stem Cells/physiology , Transplantation, Autologous
14.
Dermatology ; 237(5): 835-842, 2021.
Article in English | MEDLINE | ID: mdl-33326964

ABSTRACT

BACKGROUND: Epidermal grafting with an automatic harvesting system has been reported as a simple and efficacious procedure for stable vitiligo. However, no prospective cohort study has quantitatively evaluated the color matching and extent of repigmentation in the head and neck area by this method. OBJECTIVE: To evaluate the color matching and extent of repigmentation after pixel array epidermal grafting by image analysis software and physicians' naked eye. METHODS: Ten Asian patients with head and neck vitiligo lesions stable for at least 6 months were treated with pixel array epidermal grafting with an automatic harvesting system and post-grafting phototherapy. The patients were evaluated 1, 3, and 6 months post grafting for the percentage of repigmentation by blinded physicians' assessment and image analysis software. The color matching index of repigmentation was evaluated by measuring the melanin index in the grafted area and the juxta non-vitiliginous area. RESULTS: The average blister harvest time was 46.3 ± 9.7 min. The area percentile of repigmentation by the image analysis software were 32.3 ± 26.8, 64.6 ± 29.4, and 76.5 ± 25.9 at 1, 3, and 6 months post grafting, respectively. There were no significant differences between the physicians' assessments and the results from the image analysis software. The change in the area percentile of repigmentation between 3 and 6 months post grafting was only statistically significant using image analysis software. The grafted area achieved a color match of 83.1 ± 13.4% that of the juxta non-vitiliginous area 6 months after grafting. Three patients had repigmentation of leukotrichia. CONCLUSION: By quantitative measurement, uniform pixel array micrografts provide a very good extent of repigmentation and color match in the head and neck area. Image analysis software revealed a steady increase in repigmentation after POM3 until POM6, which was not detected by subjective assessment.


Subject(s)
Asian People , Epidermis/transplantation , Skin Pigmentation , Skin Transplantation , Vitiligo/therapy , Adult , Female , Head , Humans , Male , Middle Aged , Neck , Prospective Studies , Taiwan , Transplantation, Autologous , Treatment Outcome , Vitiligo/pathology , Young Adult
16.
Arch Dermatol Res ; 312(9): 635-645, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32107629

ABSTRACT

Postinflammatory hyperpigmentation (PIH) is a common disfiguring complication following inflammatory dermatoses and cosmetic procedures in dark-skinned individuals. Anti-inflammatory and repairing agents targeting primary inflammation and injury are becoming promising choices for preventing PIH. The aim of this active-controlled, assessor-blinded, intra-individual monocentric study was to evaluate the preventive effect of a wound-dressing biomaterial, mussel adhesive protein (MAP) in the suction blister-induced PIH model. Twenty Chinese patients underwent suction blister epidermal grafting had defined wound areas to receive a topical MAP spray or a potent corticosteroid cream once daily for seven consecutive days after operation. In situ semi-quantitative evaluations of inflammation and pigmentation were achieved by Mexameter, reflectance confocal microscopy and dermoscopy on week 1, week 4, and week 12. Topical application of MAP exerted remarkably inhibitory effect on PIH comparable to fluticasone propionate, manifested as significantly lower melanin index and papillary contrast measured by Mexameter and confocal microscopy on week 12 compared to untreated sites. Although MAP exhibited moderate anti-inflammatory effect weaker than fluticasone propionate, MAP-treated sites healed faster than steroid-treated and untreated sites. The biological activity of MAP was further studied in UVB-irradiated HaCaT cell model, which revealed MAP decreased the expression of UVB-induced α-melanocyte stimulating hormone (α-MSH) and pro-inflammatory cytokines (IL-1α, IL-6, COX-2). It also protected HaCaT cells from UVB-induced cell death and apoptosis. In conclusion, MAP could be a novel postoperational wound dressing preventing PIH associated with skin inflammation and injury.


Subject(s)
Hyperpigmentation/prevention & control , Postoperative Complications/prevention & control , Proteins/administration & dosage , Skin Transplantation/adverse effects , Vitiligo/surgery , Adult , Bandages , Biocompatible Materials/administration & dosage , Blister/complications , Blister/immunology , Cell Line , Epidermis/immunology , Epidermis/transplantation , Female , Humans , Hyperpigmentation/immunology , Male , Postoperative Complications/immunology , Skin Transplantation/methods , Suction/adverse effects , Transplant Donor Site , Treatment Outcome , Young Adult
18.
Biomed Res Int ; 2019: 7623607, 2019.
Article in English | MEDLINE | ID: mdl-31828129

ABSTRACT

BACKGROUND: Noncultured epidermal suspension (NCES) is a surgical technique which employs cellular grafting onto depigmented lesions. However, scarring and dyschromia at the donor site often occurs. OBJECTIVE: To assess the outcome of reusing the same donor site in subsequent sessions of NCES procedures. METHODS: Electronic records of vitiligo patients who had undergone two sessions of NCES procedures were retrospectively reviewed. Information on the first and second NCES was retrieved for analyses. RESULTS: A total of 30 patients (female 19 and male 11) were included. The majority of patients had nonsegmental vitiligo (66.7%). The median donor-to-recipient ratios were 1 : 3 (1 : 1-1 : 20) for the first session and 1 : 3 (1 : 1-1 : 13.5) for the second session (p=0.661). The mean melanocyte count was 220.7 ± 65.5 cells/mm2 vs. 242.4 ± 55.3 cells/mm2 on the first and second sessions, respectively (p=0.440). The mean repigmentation rate was 84.2% (±21.1%) and 82.3 (±22.1%) for the first and second NCESs, respectively (p=0.645). The frequency of color mismatch and pigment loss were similar between both sessions (p=0.706 and p=1.000). CONCLUSIONS: Repeated use of donor sites in subsequent NCES sessions gave comparable repigmentation.


Subject(s)
Cicatrix/therapy , Epidermal Cells/transplantation , Skin Pigmentation/physiology , Vitiligo/therapy , Adult , Cicatrix/physiopathology , Epidermal Cells/pathology , Epidermis/pathology , Epidermis/transplantation , Epithelial Cells/transplantation , Female , Humans , Male , Melanocytes/metabolism , Melanocytes/pathology , Middle Aged , Retrospective Studies , Transplantation, Autologous , Treatment Outcome , Vitiligo/physiopathology
19.
Hum Gene Ther ; 30(9): 1067-1078, 2019 09.
Article in English | MEDLINE | ID: mdl-31288584

ABSTRACT

Netherton syndrome (NS) is a rare autosomal recessive skin disorder caused by mutations in SPINK5. It is a debilitating condition with notable mortality in the early years of life. There is no curative treatment. We undertook a nonrandomized, open-label, feasibility, and safety study using autologous keratinocytes transduced with a lentiviral vector encoding SPINK5 under the control of the human involucrin promoter. Six NS subjects were recruited, and gene-modified epithelial sheets were successfully generated in three of five subjects. The sheets exhibited expression of correctly sized lympho-epithelial Kazal-type-related inhibitor (LEKTI) protein after modification. One subject was grafted with a 20 cm2 gene-modified graft on the left anterior thigh without any adverse complications and was monitored by serial sampling for 12 months. Recovery within the graft area was compared against an area outside by morphology, proviral copy number and expression of the SPINK5 encoded protein, LEKTI, and its downstream target kallikrein 5, which exhibited transient functional correction. The study confirmed the feasibility of generating lentiviral gene-modified epidermal sheets for inherited skin diseases such as NS, but sustained LEKTI expression is likely to require the identification, targeting, and engraftment of long-lived keratinocyte stem cell populations for durable therapeutic effects. Important learning points for the application of gene-modified epidermal sheets are discussed.


Subject(s)
Epidermal Cells/metabolism , Epidermis/metabolism , Epidermis/transplantation , Netherton Syndrome/genetics , Netherton Syndrome/therapy , Transduction, Genetic , Transgenes , Adolescent , Adult , Autografts , Biomarkers , Cell Culture Techniques , Female , Fluorescent Antibody Technique , Gene Expression , Genetic Engineering , Genetic Therapy , Genetic Vectors/administration & dosage , Genetic Vectors/genetics , Humans , Immunohistochemistry , Keratinocytes/metabolism , Lentivirus/genetics , Male , Mutation , Netherton Syndrome/metabolism , Netherton Syndrome/pathology , Serine Peptidase Inhibitor Kazal-Type 5/genetics , Serine Peptidase Inhibitor Kazal-Type 5/metabolism , Treatment Outcome , Young Adult
20.
Plast Reconstr Surg ; 144(1): 188-198, 2019 07.
Article in English | MEDLINE | ID: mdl-31246829

ABSTRACT

BACKGROUND: The management of deep partial-thickness and full-thickness skin defects remains a significant challenge. Particularly with massive defects, the current standard treatment, split-thickness skin grafting, is fraught with donor-site limitations and unsatisfactory long-term outcomes. A novel, autologous, bioengineered skin substitute was developed to address this problem. METHODS: To determine whether this skin substitute could safely provide permanent defect coverage, a phase I clinical trial was performed at the University Children's Hospital Zurich. Ten pediatric patients with acute or elective deep partial- or full-thickness skin defects were included. Skin grafts of 49 cm were bioengineered using autologous keratinocytes and fibroblasts isolated from a patient's small skin biopsy specimen (4 cm), incorporated in a collagen hydrogel. RESULTS: Graft take, epithelialization, infection, adverse events, skin quality, and histology were analyzed. Median graft take at 21 days postoperatively was 78 percent (range, 0 to 100 percent). Healed skin substitutes were stable and skin quality was nearly normal. There were four cases of hematoma leading to partial graft loss. Histology at 3 months revealed a well-stratified epidermis and a dermal compartment comparable to native skin. Mean follow-up duration was 15 months. CONCLUSIONS: In the first clinical application of this novel skin substitute, safe coverage of skin defects was achieved. Safety and efficacy phase II trials comparing the novel skin substitute to split-thickness skin grafts are ongoing. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.


Subject(s)
Burns/surgery , Skin Transplantation/methods , Skin, Artificial , Skin/injuries , Adolescent , Bioengineering , Cells, Cultured , Child , Child, Preschool , Dermis/cytology , Dermis/transplantation , Epidermal Cells/transplantation , Epidermis/transplantation , Female , Fibroblasts/transplantation , Humans , Infant , Keratinocytes/transplantation , Male , Prospective Studies , Transplantation, Autologous
SELECTION OF CITATIONS
SEARCH DETAIL
...